Advertisement

Topics

Pharmerica Corporation (PMC) Stock Rating Upgraded by Zacks Investment Research

08:46 EDT 29 Sep 2017 | Topix

The firm presently has a $33.00 target price on the stock. Zacks Investment Research 's price objective indicates a potential upside of 12.82% from the stock's current price.

Original Article: Pharmerica Corporation (PMC) Stock Rating Upgraded by Zacks Investment Research

NEXT ARTICLE

More From BioPortfolio on "Pharmerica Corporation (PMC) Stock Rating Upgraded by Zacks Investment Research"

Quick Search
Advertisement